OTC · Biotechnology

RenovaCare, Inc. (RCAR) Stock

$0.00 OTC: RCAR Healthcare

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area.

Valuation

MetricValue
Price$0.00
Market Cap$8735
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-0.06
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-568.90%
ROA-103.99%
ROCE-230.49%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.62

Annual Financials (USD)

Metric20172018201920202021
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-2.0M$-4.0M$-10.0M$-5.0M
Net Profit$-4.0M$-2.0M$-3.0M$-10.0M$-4.0M
EPS$-0.05$-0.03$-0.04$-0.11$-0.05
Op Margin—————

Balance Sheet (USD)

Metric20172018201920202021
Total Assets$3.0M$16.0M$12.0M$8.0M$4.0M
Total Liabilities$1.0M$0$0$1.0M$1.0M
Cash$3.0M$15.0M$12.0M$7.0M$3.0M
Borrowings$1.0M$0$0$0$0

Cash Flow (USD)

Metric20172018201920202021
Operating Cash Flow$-2.0M$-2.0M$-3.0M$-5.0M$-5.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$4.0M$15.0M$0$0$0
Net Cash Flow$2.0M$12.0M$-3.0M$-5.0M$-5.0M
Free Cash Flow$-2.0M$-2.0M$-3.0M$-5.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.52
FCF Yield-52247.02%
Quick Ratio2.59
Interest Coverage—
Return 1Y0.00%
Return 3Y0.00%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.97 +1.29% 38.93 $5.01T 0.32%
MSFTMicrosoft Corporation $541.15 +1.14% 28.68 $4.02T 0.76%
GOOGLAlphabet Inc. $352.72 +0.30% 16.94 $4.27T 0.26%
AMZNAmazon.com, Inc. $259.53 -1.11% 19.82 $2.79T 0.00%
METAMeta Platforms, Inc. $742.96 +3.38% 27.93 $1.89T 0.28%

About RenovaCare, Inc.

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.

RenovaCare, Inc. (RCAR) stock trades at $0.00 with a market capitalization of $8735. The stock is valued at price-to-book of 0.00, price-to-sales of 0.00.

On profitability, RenovaCare, Inc. generates a return on equity (ROE) of -568.90% (negative, reflecting a net loss), return on capital employed of -230.49%.

Official website: www.renovacareinc.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1182.62 +0.28% JNJ Johnson & Johnson $263.73 +0.88% ABBV AbbVie Inc. $281.04 +1.65% MRK Merck & Company, Inc. Common Stock (new) $145.45 -0.10% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.52 -0.21% NVS Novartis AG $143.84 +0.06% AZN AstraZeneca PLC $158.33 -0.55% TMO Thermo Fisher Scientific Inc $662.24 +0.64% AMGN Amgen Inc. $417.57 +0.65% GILD Gilead Sciences, Inc. $150.43 -0.49% ABT Abbott Laboratories $101.82 +2.23% NVO Novo Nordisk A/S $38.58 -0.16%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.